JP2022530216A - 免疫グロブリンのFc領域およびGDF15を含む融合ポリペプチド - Google Patents
免疫グロブリンのFc領域およびGDF15を含む融合ポリペプチド Download PDFInfo
- Publication number
- JP2022530216A JP2022530216A JP2021562863A JP2021562863A JP2022530216A JP 2022530216 A JP2022530216 A JP 2022530216A JP 2021562863 A JP2021562863 A JP 2021562863A JP 2021562863 A JP2021562863 A JP 2021562863A JP 2022530216 A JP2022530216 A JP 2022530216A
- Authority
- JP
- Japan
- Prior art keywords
- gdf15
- region
- seq
- fusion polypeptide
- functional variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 162
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 136
- 230000004927 fusion Effects 0.000 title claims abstract description 135
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 135
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 71
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 71
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 title description 2
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 title description 2
- 230000001965 increasing effect Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 238000009792 diffusion process Methods 0.000 claims abstract description 4
- 239000013598 vector Substances 0.000 claims description 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 239000000539 dimer Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 30
- 150000007523 nucleic acids Chemical class 0.000 claims description 30
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 230000004580 weight loss Effects 0.000 claims description 23
- 208000030159 metabolic disease Diseases 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 235000005911 diet Nutrition 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 6
- 230000000378 dietary effect Effects 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000016097 disease of metabolism Diseases 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 238000012360 testing method Methods 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 32
- 230000000694 effects Effects 0.000 description 29
- 239000000126 substance Substances 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 25
- 208000016261 weight loss Diseases 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 230000037396 body weight Effects 0.000 description 18
- 235000021050 feed intake Nutrition 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 102100040304 GDNF family receptor alpha-like Human genes 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 7
- 235000009200 high fat diet Nutrition 0.000 description 7
- 229950011186 semaglutide Drugs 0.000 description 7
- 108010060325 semaglutide Proteins 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000000638 solvent extraction Methods 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002716 delivery method Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000035859 Drug effect increased Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000013878 renal filtration Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000593245 Bionia Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710174136 GDNF family receptor alpha-like Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101100386050 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-14 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 1
- 101100007331 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS3 gene Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000046181 human GDF15 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
GDF15は、全体308個アミノ酸(UniProt Q99988)の中でsignal peptideとpropeptideを除いた、197番目(A)から308番目(I)までのアミノ酸(配列番号1;図2参照;mature form)で構成されている。
GDF15またはその機能的変異体と融合する免疫グロブリンのFcは、前記GDF15またはその機能的変異体の安定性を増進させる役割を果たすもので、例えば、半減期(e.g.,体内半減期)を延長、および/またはrenal filtration減少などの効果を有する。一例として、前記免疫グロブリンのFc領域は、IgG1のFcおよびIgG4のFcの中から選択される。前記IgG1のFc領域は、IgG1のCH2ドメイン、CH3ドメイン、またはCH2+CH3ドメインを含み、N-末端にIgG1のヒンジ領域を含むか、または含まない。IgG4のFc領域は、IgG4のCH2ドメイン、CH3ドメイン、またはCH2+CH3ドメインを含み、N-末端にIgG4のヒンジ領域を含むか、または含まない。
一実施形態において、前記免疫グロブリンのFc領域は、ヒトIgG4 FcのCH2-CH3ドメイン(配列番号5(一般式);配列番号6(野生型)、または配列番号7、8、または9(変異型)を含むか、前記CH2-CH3ドメインのN末端にヒトIgG4のヒンジ領域(配列番号10(一般式);配列番号11(野生型)、または配列番号12(変異型))をさらに含む。
本明細書で使用される融合ポリペプチドは、免疫グロブリンのFc領域および前記免疫グロブリンのFc領域のC-末端に連結されたGDF15またはその機能的変異体を含む。前記免疫グロブリンのFc領域およびGDF15またはその機能的変異体は上述した通りである。
GDF15の機能的に活性のある形態は同種二量体(homo dimer)形態である。
GDF15またはその機能的変異体と免疫グロブリンのFc領域を含む融合ポリペプチドは、通常の化学的合成方法または組換え方法によって生産され、天然由来(naturally occurring)のものではないこともある。
融合ポリペプチド、融合ポリペプチド二量体、融合ポリペプチドコード核酸分子、前記核酸分子を含む組換えベクター、および前記組換えベクターを含む組換え細胞からなる群より選択される1つ以上を含む、体重減少、食餌調節(食事量の減少)、または代謝性疾患の予防、改善、軽減、および/または治療用組成物(薬学組成物または健康機能性食品組成物);および/または前記融合ポリペプチド、融合ポリペプチド二量体、融合ポリペプチドコード核酸分子、前記核酸分子を含む組換えベクター、および前記組換えベクターを含む組換え細胞からなる群より選択される1つ以上の薬学的有効量を代謝性疾患の予防、改善、軽減、および/または治療を必要とする対象に投与する段階を含む、体重減少方法、食餌調節(食事量の減少)方法、または代謝性疾患の予防、改善、軽減、および/または治療方法が提供される。
1.1.融合ポリペプチドをコードする遺伝子のクローニングおよび培養
Hingeが含まれるかまたは含まれない免疫グロブリンFc(IgG1-Fc(ヒンジ含まず:配列番号3;HIgG1-Fc(ヒンジ含む;[配列番号4]-[配列番号3])、Mutated IgG4-Fc(ヒンジ含まず;配列番号7)またはMutated HIgG4-Fc(ヒンジ含む:[配列番号12]-[配列番号7])が目的ポリペプチドのMature GDF15(GDFまたはGDF15で表示;配列番号1)、またはGDF15変異体(GDF(CRL)で表示;N末端14個のアミノ酸欠失:配列番号2)と融合した融合ポリペプチドIgG1-GDF(CRL)、HIgG1-GDF(CRL)、IgG4-GDF、HIgG4-GDF、IgG4-GDF(CRL)、およびHIgG4-GDF(CRL)(図1参照)を製造した。前記融合ポリペプチドに含まれている各部分のアミノ酸配列を下記の表2、表3および表4に整理した。
1.1.1.1.Mature GDF15
Mature GDF15をコードする遺伝子を得るために、UniprotKB Q99968のアミノ酸を参照してMature GDF15をコードする遺伝子(配列番号14)をバイオニア社で合成した。
配列番号14(339bp)
1 GCCCGGAACG GCGACCACTG CCCCCTGGGG CCCGGACGGT GCTGCCGGCT
51 GCACACCGTG CGGGCCTCCC TGGAGGACCT GGGCTGGGCC GACTGGGTGC
101 TGTCCCCAAG GGAGGTGCAA GTGACCATGT GCATCGGCGC CTGCCCATCT
151 CAGTTCCGGG CCGCCAACAT GCACGCTCAG ATCAAGACCA GCCTGCACCG
201 GCTGAAGCCC GACACCGTGC CCGCCCCCTG CTGCGTGCCC GCCTCCTACA
251 ACCCCATGGT GCTGATTCAG AAGACCGACA CCGGCGTGAG CCTGCAGACC
301 TACGACGACC TGCTGGCCAA GGACTGCCAC TGCATCTAA
(*アンダーライン部分がGDF(CRL)である)
Hingeを含むヒトIgG1 Fcをコードする遺伝子またはHingeを含まないヒトIgG1 Fcをコードする遺伝子は、ヒトIgG1のcore HingeとIgG1 Fcをコードする遺伝子を含んでいるプラスミドを用いてPCRにより得た。
配列番号15(678bp)
1 GACAAAACTC ACACATGCCC ACCGTGCCCA GCACCTGAAC TCCTGGGGGG
51 ACCGTCAGTC TTCCTCTTCC CCCCAAAACC CAAGGACACC CTCATGATCT
101 CCCGGACCCC TGAGGTCACA TGCGTGGTGG TGGACGTGAG CCACGAAGAC
151 CCTGAGGTCA AGTTCAACTG GTACGTGGAC GGCGTGGAGG TGCATAATGC
201 CAAGACAAAG CCGCGGGAGG AGCAGTACAA CAGCACGTAC CGTGTGGTCA
251 GCGTCCTCAC CGTCCTGCAC CAGGACTGGC TGAATGGCAA GGAGTACAAG
301 TGCAAGGTCT CCAACAAAGC CCTCCCAGCC CCCATCGAGA AAACCATCTC
351 CAAAGCCAAA GGGCAGCCCC GAGAACCACA GGTGTATACC CTGCCCCCAT
401 CCCGGGATGA GCTGACCAAG AACCAGGTCA GCCTGACCTG CCTGGTCAAA
451 GGCTTCTATC CCAGCGACAT CGCCGTGGAG TGGGAGAGCA ATGGGCAGCC
501 GGAGAACAAC TACAAGACCA CGCCTCCCGT GCTGGACTCC GACGGCTCCT
551 TCTTCCTCTA CAGCAAGCTC ACCGTGGACA AGAGCAGGTG GCAGCAGGGG
601 AACGTCTTCT CATGCTCCGT GATGCATGAG GCTCTGCACA ACCACTACAC
651 GCAGAAGAGC CTCTCCCTGT CTCCGGGT
(*アンダーライン部分がIgG1 Core Hingeをコードする遺伝子である)
Hingeを含むヒトIgG4 Fcをコードする遺伝子またはHingeを含まないヒトIgG4 Fcをコードする遺伝子は、ヒトIgG4のHingeとIgG4 Fcをコードする遺伝子を含んでいるプラスミドを用いてPCRにより得た。
配列番号16(684bp)
1 GAGTCCAAAT ATGGTCCCCC ATGCCCACCC TGCCCAGCAC CTGAGGCCGC
51 CGGGGGACCG TCAGTCTTCC TCTTCCCCCC AAAACCCAAG GACACCCTCA
101 TGATCTCCCG GACCCCTGAG GTCACGTGCG TGGTGGTGGA CGTGTCCCAG
151 GAGGACCCCG AGGTGCAGTT CAACTGGTAC GTGGACGGCG TGGAGGTGCA
201 CAACGCCAAG ACCAAGCCCC GGGAGGAGCA GTTCAACTCC ACCTACCGGG
251 TGGTGTCCGT GCTGACCGTG CTGCACCAGG ACTGGCTGAA CGGCAAGGAG
301 TACAAGTGCA AGGTGTCCAA CAAGGGCCTG CCCTCCTCCA TCGAGAAGAC
351 CATCTCCAAG GCCAAGGGCC AGCCCCGGGA GCCCCAGGTG TACACCCTGC
401 CCCCCTCCCA GGAGGAGATG ACCAAGAACC AGGTGTCCCT GACCTGCCTG
451 GTGAAGGGCT TCTACCCCTC CGACATCGCC GTGGAGTGGG AGTCCAACGG
501 CCAGCCCGAG AACAACTACA AGACCACCCC CCCCGTGCTG GACTCCGACG
551 GCTCCTTCTT CCTGTACTCC CGGCTGACCG TGGACAAGTC CCGGTGGCAG
601 GAGGGCAACG TGTTCTCCTG CTCCGTGATG CACGAGGCCC TGCACAACCA
651 CTACACCCAG AAGTCCCTGT CCCTGTCCCT GGGC
(*アンダーライン部分がIgG4 Hingeをコードする遺伝子である)
pcDNA3.1(+)(Invitrogen,Cat.No.V790-20)の変形体であるpDHDD-D1G1(KR10-1868139B1のPromoterを含む)をBamHIおよびNotIで切断し、そこに前記遺伝子(Mature GDF15、IgG1-Fc、IgG4-Fc)を組み合わせて下記の構造(図4参照)を有する遺伝子を挿入してそれぞれの組換えベクターを用意した。
‘(N-末端)-[BamHI制限部位-シグナルペプチド(配列番号17)-IgG1 Core Hinge(配列番号4)-IgG1 CH2-CH3(配列番号3)-GS Linker(配列番号18)-GDF(CRL)(配列番号2)-NotI制限部位]-(C-末端)’
‘(N-末端)-[BamHI制限部位-シグナルペプチド(配列番号17)-IgG1 CH2-CH3(配列番号3)-GS Linker(配列番号18)-GDF(CRL)(配列番号2)-NotI制限部位]-(C-末端)’
‘(N-末端)-[BamHI制限部位-シグナルペプチド(配列番号17)-IgG4 Hinge(配列番号12)-IgG4 CH2-CH3(配列番号7)-GS Linker(配列番号18)-GDF15(配列番号1)-NotI制限部位]-(C-末端)’
‘(N-末端)-[BamHI制限部位-シグナルペプチド(配列番号17)-IgG4 CH2-CH3(配列番号7)-GS Linker(配列番号18)-GDF15(配列番号1)-NotI制限部位]-(C-末端)’
‘(N-末端)-[BamHI制限部位-シグナルペプチド(配列番号17)-IgG4 Hinge(配列番号12)-IgG4 CH2-CH3(配列番号7)-GS Linker(配列番号18)-GDF(CRL)(配列番号2)-NotI制限部位]-(C-末端)’
‘(N-末端)-[BamHI制限部位-シグナルペプチド(配列番号17)-IgG4 CH2-CH3(配列番号7)-GS Linker(配列番号18)-GDF(CRL)(配列番号2)-NotI制限部位]-(C-末端)’
前記用意された組換え発現ベクターpHIgG1-GDF(CRL)、pIgG1-GDF(CRL)、pHIgG4-GDF(CRL)、pIgG4-GDF(CRL)、pHIgG4-GDFおよびpIgG4-GDFをExpiCHO-STM細胞(Thermo Fisher Scientific)に導入し、ExpiCHO Expression Medium(Thermo Fisher Scientific;400mL)で12日間培養(Fed-Batch Culture;Day1&Day5 Feeding)して、前記融合ポリペプチドHIgG1-GDF(CRL)、IgG1-GDF(CRL)、HIgG4-GDF(CRL)、IgG4-GDF(CRL)、HIgG4-GDFおよびIgG4-GDFを発現させた。
プロテインA親和性クロマトグラフィー(Protein A Affinity Chromatography)を用いて前記実施例1.1で用意された細胞培養物から融合ポリペプチドを精製した。
2.1.試験過程
前記実施例1で生産および精製された融合ポリペプチドの薬理効果をmouse(C57BL/6J、6週齢、雄、100匹;ラオンバイオ(株))で試験した。
5.24kcal/g、脂肪60重量%、タンパク質20重量%、およびcarbohydrate-derived calories20重量%;Research Diet Inc.,U.S.A.;Product No.High fat diet(Fat 60kcal%、D12492)。
試験物質(HIgG1-GDF(CRL)とIgG1-GDF(CRL))と対照物質GDF15(R&D Systems)投与は、群分離した後翌日から行い、投与時間は毎日午前9時に行った。対照物質および試験物質いずれも皮下投与した。前記対照物質および試験物質の投与経路は、予定臨床投与経路によって皮下経路を選択した。
試験物質(IgG4-GDFおよびIgG4-GDF(CRL))と対照物質Semaglutide(Bachem)全てに皮下投与した。対照物質および試験物質いずれも投与液量を5mL/kgとし、個体別投与液量は、最近測定した体重を基準にして算出し、使い捨て注射器(1mL)を用いて試験開始日に1回皮下内に注射投与した。試験物質は試験開始日に1回のみを投与し、比較のために、対照物質Semaglutideを投与した対照群を用意し、Semaglutideを投与した比較群の場合1日1回ずつ連日投与し、すべての投与は午前9時から行った。
2.2.1.HIgG1-GDF(CRL)and IgG1-GDF(CRL)
前記実施例2.1.1で測定された体重変化を図5および図6、および表9(Body Weight(Group、% of initial)に示す。
2.3.1.HIgG1-GDF(CRL)およびIgG1-GDF(CRL)
前記実施例2.1.1で測定された飼料摂取量の変化を表11および図9(6日目までの累積摂取量)にそれぞれ示す。
3.1.試験群および対照群の血清の用意
各ポリペプチドをラットに皮下投与時の薬物動態学的特性評価のために、ポリペプチドIgG4-GDFまたはIgG4-GDF(CRL)をSD Rat(コアテック社製、雄、7週齢、約250g;各n=3;試験群)にそれぞれ2mg/kgの量で皮下投与して定めた時間に尾静脈を通して約200ul程度の採血を行った。採血時間は、融合ポリペプチド投与前、投与後、1、2、4、8、24、48、72、96、168、240および336時間に行った。薬物動態学的特性の比較のための対照群で、上記と同様の方法でGDF15(R&D Systems)を2mg/kgの量で皮下投与してGDF15投与群を用意した。
Claims (21)
- GDF15(Growth/differentiation factor 15)またはその機能的変異体、および
免疫グロブリンのFc領域を含み、
前記免疫グロブリンのFc領域は単一鎖のIgG1 Fc領域またはIgG4 Fc領域であり、前記GDF15またはその機能的変異体のN-末端にフレキシブルペプチドリンカーを介して連結され、
前記GDF15の機能的変異体は、配列番号1のアミノ酸配列のうちの1番目から14番目までの14個アミノ酸中の1つ以上が欠失した欠失変異体であり、
前記フレキシブルペプチドリンカーは(GGGGS)n(nは1、2、3、4または5)で表される、融合ポリペプチド。 - 前記免疫グロブリンのFc領域はヒトIgG4 Fc領域である、請求項1に記載の融合ポリペプチド。
- 前記ヒトIgG4 Fc領域は、
(1)配列番号5のアミノ酸配列を含むか、
(2)配列番号5のアミノ酸配列のN末端に配列番号10のアミノ酸配列をさらに含む、請求項2に記載の融合ポリペプチド。 - 前記ヒトIgG4 Fc領域は、
(1)配列番号6~9の中から選択されるアミノ酸配列を含むか、
(2)配列番号6~9の中から選択されるアミノ酸配列のN末端に配列番号11または配列番号12のアミノ酸配列をさらに含む、請求項3に記載の融合ポリペプチド。 - 前記GDF15の機能的変異体は、配列番号2のアミノ酸配列を含む、請求項1に記載の融合ポリペプチド。
- 前記融合ポリペプチド内の免疫グロブリンのFc領域と連結されたGDF15またはその機能的変異体は、免疫グロブリンのFc領域と結合しないGDF15またはその機能的変異体に比べて、体内半減期が1.5倍以上増加する、請求項1~5のいずれか一項に記載の融合ポリペプチド。
- 請求項1~5のいずれか一項に記載の融合ポリペプチドを2つ含む、融合ポリペプチド二量体。
- 請求項1~5のいずれか一項に記載の融合ポリペプチドをコードする、核酸分子。
- 請求項8に記載の核酸分子を含む、組換えベクター。
- 請求項9に記載の組換えベクターを含む、組換え細胞。
- 請求項10に記載の組換え細胞を培養する段階を含む、GDF15またはその機能的変異体および免疫グロブリンのFc領域を含む、融合ポリペプチドの製造方法。
- 単一鎖のIgG1 Fc領域またはIgG4 Fc領域をGDF15またはその機能的変異体のN末端にフレキシブルペプチドリンカーを介して連結させる段階を含み、
前記GDF15の機能的変異体は、配列番号1のアミノ酸配列のうちの1番目から14番目までの14個アミノ酸中の1つ以上が欠失した欠失変異体であり、
前記フレキシブルペプチドリンカーは(GGGGS)n[(配列番号13)n;nは、1、2、3、4または5]で表される、GDF15またはその機能的変異体の体内安定性増進方法。 - 前記免疫グロブリンのFc領域はヒトIgG4 Fc領域である、請求項12に記載のGDF15またはその機能的変異体の体内安定性増進方法。
- 前記ヒトIgG4 Fc領域は、
(1)配列番号5のアミノ酸配列を含むか、
(2)配列番号5のアミノ酸配列のN末端に配列番号10のアミノ酸配列をさらに含む、請求項13に記載のGDF15またはその機能的変異体の体内安定性増進方法。 - 前記ヒトIgG4 Fc領域は、
(1)配列番号6~配列番号9の中から選択されるアミノ酸配列を含むか、
(2)配列番号6~配列番号9の中から選択されるアミノ酸配列のN末端に配列番号11または配列番号12のアミノ酸配列をさらに含む、請求項14に記載のGDF15またはその機能的変異体の体内安定性増進方法。 - 前記GDF15の機能的変異体は、配列番号2のアミノ酸配列を含む、請求項12に記載のGDF15またはその機能的変異体の体内安定性増進方法。
- 前記免疫グロブリンのFc領域と連結されたGDF15またはその機能的変異体は、免疫グロブリンのFc領域と結合しないGDF15またはその機能的変異体に比べて、体内半減期が1.5倍以上増加する、請求項12~16のいずれか一項に記載のGDF15またはその機能的変異体の体内安定性増進方法。
- 請求項1~5のいずれか一項に記載の融合ポリペプチド、前記融合ポリペプチドを2つ含む融合ポリペプチド二量体、前記融合ポリペプチドをコードする核酸分子、前記核酸分子を含む組換えベクター、および前記組換えベクターを含む組換え細胞からなる群より選択される1つ以上を含む、体重減少用組成物。
- 請求項1~5のいずれか一項に記載の融合ポリペプチド、前記融合ポリペプチドを2つ含む融合ポリペプチド二量体、前記融合ポリペプチドをコードする核酸分子、前記核酸分子を含む組換えベクター、および前記組換えベクターを含む組換え細胞からなる群より選択される1つ以上を含む、食餌調節用組成物。
- 請求項1~5のいずれか一項に記載の融合ポリペプチド、前記融合ポリペプチドを2つ含む融合ポリペプチド二量体、前記融合ポリペプチドをコードする核酸分子、前記核酸分子を含む組換えベクター、および前記組換えベクターを含む組換え細胞からなる群より選択される1つ以上を含む、代謝性疾患の予防または治療用薬学組成物。
- 前記代謝性疾患は、肥満、糖尿病、または非アルコール性脂肪肝疾患である、請求項20に記載の薬学組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023101082A JP2023115118A (ja) | 2019-04-23 | 2023-06-20 | 免疫グロブリンのFc領域およびGDF15を含む融合ポリペプチド |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190047558 | 2019-04-23 | ||
KR10-2019-0047558 | 2019-04-23 | ||
PCT/KR2020/005324 WO2020218827A1 (ko) | 2019-04-23 | 2020-04-22 | 면역글로불린의 Fc 영역 및 GDF15를 포함하는 융합 폴리펩타이드 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023101082A Division JP2023115118A (ja) | 2019-04-23 | 2023-06-20 | 免疫グロブリンのFc領域およびGDF15を含む融合ポリペプチド |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022530216A true JP2022530216A (ja) | 2022-06-28 |
Family
ID=72941168
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021562863A Pending JP2022530216A (ja) | 2019-04-23 | 2020-04-22 | 免疫グロブリンのFc領域およびGDF15を含む融合ポリペプチド |
JP2023101082A Pending JP2023115118A (ja) | 2019-04-23 | 2023-06-20 | 免疫グロブリンのFc領域およびGDF15を含む融合ポリペプチド |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023101082A Pending JP2023115118A (ja) | 2019-04-23 | 2023-06-20 | 免疫グロブリンのFc領域およびGDF15を含む融合ポリペプチド |
Country Status (18)
Country | Link |
---|---|
US (1) | US20230053119A1 (ja) |
EP (1) | EP3978518A4 (ja) |
JP (2) | JP2022530216A (ja) |
KR (2) | KR20200124176A (ja) |
CN (1) | CN113767112A (ja) |
AU (1) | AU2020260931B2 (ja) |
BR (1) | BR112021021271A2 (ja) |
CA (1) | CA3136969A1 (ja) |
CL (1) | CL2021002757A1 (ja) |
CO (1) | CO2021014413A2 (ja) |
IL (1) | IL287343A (ja) |
JO (1) | JOP20210282A1 (ja) |
MX (1) | MX2021012964A (ja) |
PE (1) | PE20220500A1 (ja) |
SG (1) | SG11202111570TA (ja) |
TW (2) | TW202337914A (ja) |
WO (1) | WO2020218827A1 (ja) |
ZA (1) | ZA202108437B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022278933A1 (en) * | 2021-05-21 | 2023-12-07 | Yuhan Corporation | Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant |
WO2023025123A1 (zh) * | 2021-08-24 | 2023-03-02 | 广东东阳光药业有限公司 | Gdf15融合蛋白及其用途 |
WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015506373A (ja) * | 2012-01-26 | 2015-03-02 | アムジエン・インコーポレーテツド | 成長分化因子15(gdf−15)ポリペプチド |
JP2016511752A (ja) * | 2013-01-30 | 2016-04-21 | エヌジーエム バイオファーマシューティカルズ インコー | 代謝障害の処置における組成物及び使用方法 |
JP2016532690A (ja) * | 2013-07-31 | 2016-10-20 | アムジエン・インコーポレーテツド | 増殖分化因子15(gdf−15)の構築物 |
WO2017196647A1 (en) * | 2016-05-10 | 2017-11-16 | Janssen Biotech, Inc. | Gdf15 fusion proteins and uses thereof |
WO2019199685A1 (en) * | 2018-04-09 | 2019-10-17 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8846874B2 (en) | 2003-11-13 | 2014-09-30 | Hanmi Science Co., Ltd | IgG Fc fragment for a drug carrier and method for the preparation thereof |
KR101038126B1 (ko) | 2010-11-30 | 2011-05-31 | 주식회사 엘지생명과학 | 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터 |
KR101868139B1 (ko) | 2010-11-30 | 2018-06-15 | 주식회사 엘지화학 | 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터 |
EP3415528B1 (en) * | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
CA2862516C (en) * | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
KR102092225B1 (ko) | 2014-04-30 | 2020-03-23 | 주식회사 엘지화학 | 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터 |
US10588980B2 (en) * | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
CA2961587A1 (en) * | 2014-10-31 | 2016-05-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
AU2016262845B2 (en) * | 2015-05-18 | 2020-07-23 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
CA3003109A1 (en) * | 2015-10-28 | 2017-05-04 | Yuhan Corporation | Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same |
EP3393494A1 (en) * | 2015-12-22 | 2018-10-31 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
-
2020
- 2020-04-22 TW TW112122841A patent/TW202337914A/zh unknown
- 2020-04-22 MX MX2021012964A patent/MX2021012964A/es unknown
- 2020-04-22 US US17/605,798 patent/US20230053119A1/en active Pending
- 2020-04-22 EP EP20793990.1A patent/EP3978518A4/en active Pending
- 2020-04-22 CN CN202080030773.8A patent/CN113767112A/zh active Pending
- 2020-04-22 PE PE2021001749A patent/PE20220500A1/es unknown
- 2020-04-22 JP JP2021562863A patent/JP2022530216A/ja active Pending
- 2020-04-22 AU AU2020260931A patent/AU2020260931B2/en active Active
- 2020-04-22 SG SG11202111570TA patent/SG11202111570TA/en unknown
- 2020-04-22 KR KR1020200048925A patent/KR20200124176A/ko active Application Filing
- 2020-04-22 TW TW109113479A patent/TW202100563A/zh unknown
- 2020-04-22 WO PCT/KR2020/005324 patent/WO2020218827A1/ko active Application Filing
- 2020-04-22 BR BR112021021271A patent/BR112021021271A2/pt unknown
- 2020-04-22 CA CA3136969A patent/CA3136969A1/en active Pending
- 2020-04-22 JO JOP/2021/0282A patent/JOP20210282A1/ar unknown
-
2021
- 2021-06-24 KR KR1020210082625A patent/KR102609627B1/ko active IP Right Grant
- 2021-10-18 IL IL287343A patent/IL287343A/en unknown
- 2021-10-20 CL CL2021002757A patent/CL2021002757A1/es unknown
- 2021-10-27 CO CONC2021/0014413A patent/CO2021014413A2/es unknown
- 2021-10-29 ZA ZA2021/08437A patent/ZA202108437B/en unknown
-
2023
- 2023-06-20 JP JP2023101082A patent/JP2023115118A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015506373A (ja) * | 2012-01-26 | 2015-03-02 | アムジエン・インコーポレーテツド | 成長分化因子15(gdf−15)ポリペプチド |
JP2016511752A (ja) * | 2013-01-30 | 2016-04-21 | エヌジーエム バイオファーマシューティカルズ インコー | 代謝障害の処置における組成物及び使用方法 |
JP2016532690A (ja) * | 2013-07-31 | 2016-10-20 | アムジエン・インコーポレーテツド | 増殖分化因子15(gdf−15)の構築物 |
WO2017196647A1 (en) * | 2016-05-10 | 2017-11-16 | Janssen Biotech, Inc. | Gdf15 fusion proteins and uses thereof |
WO2019199685A1 (en) * | 2018-04-09 | 2019-10-17 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
Non-Patent Citations (1)
Title |
---|
DRUG DELIVERY SYSTEM, vol. 26-6, JPN6023010686, 2011, pages 611 - 621, ISSN: 0005015710 * |
Also Published As
Publication number | Publication date |
---|---|
CN113767112A (zh) | 2021-12-07 |
TW202100563A (zh) | 2021-01-01 |
ZA202108437B (en) | 2023-07-26 |
JP2023115118A (ja) | 2023-08-18 |
KR102609627B1 (ko) | 2023-12-04 |
MX2021012964A (es) | 2021-12-10 |
CO2021014413A2 (es) | 2021-11-19 |
PE20220500A1 (es) | 2022-04-07 |
BR112021021271A2 (pt) | 2021-12-21 |
SG11202111570TA (en) | 2021-11-29 |
EP3978518A4 (en) | 2022-11-02 |
KR20200124176A (ko) | 2020-11-02 |
TW202337914A (zh) | 2023-10-01 |
EP3978518A1 (en) | 2022-04-06 |
IL287343A (en) | 2021-12-01 |
AU2020260931A1 (en) | 2021-12-09 |
JOP20210282A1 (ar) | 2023-01-30 |
WO2020218827A1 (ko) | 2020-10-29 |
CL2021002757A1 (es) | 2022-06-10 |
AU2020260931B2 (en) | 2023-08-24 |
KR20210080339A (ko) | 2021-06-30 |
CA3136969A1 (en) | 2020-10-29 |
US20230053119A1 (en) | 2023-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102609627B1 (ko) | 면역글로불린의 Fc 영역 및 GDF15를 포함하는 융합 폴리펩타이드 | |
AU2014236451B2 (en) | Apelin fusion proteins and uses thereof | |
WO2018032787A1 (zh) | 高糖基化人生长激素融合蛋白及其制备方法与用途 | |
CA2404945C (en) | Taci as an anti-tumor agent | |
KR20060124656A (ko) | 개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질 | |
US20040067520A1 (en) | OB fusion protein compositions and methods | |
KR20160038896A (ko) | 성장 분화 인자 15(gdf-15) 작제물 | |
JP2008506635A (ja) | Fgf−21融合タンパク質 | |
PT1699822E (pt) | Proteínas de fusão de il-7 | |
CN107484416A (zh) | 能够结合cd19和cd3的双特异性单价双抗体及其用途 | |
CN110066341A (zh) | 蛋白、缀合物、药物组合物、DNA构建体、宿主细胞及制备人SIRPα融合蛋白的方法 | |
HUE029789T2 (en) | Trimer OX40 Immunoglobulin Fusion Protein and Methods of Application | |
KR20140125803A (ko) | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 | |
JP2003530874A (ja) | 貧血の予防及び治療用の方法及び組成物 | |
KR20000069617A (ko) | Ob 융합 단백질 조성물과 그 제조 방법 | |
KR20080050576A (ko) | 키메릭 치료제 | |
CN104066845A (zh) | 可溶性IGF受体Fc融合蛋白和其用途 | |
US10781248B2 (en) | α1-antitrypsin compositions and methods of treating autoimmune diseases | |
KR20160010618A (ko) | 감소된 면역원성을 갖는 개질된 박테리오파아지 g3p 아미노산 서열을 포함하는 폴리펩티드 | |
CN108424460A (zh) | GLP-1类似物和davalintide类似物的融合蛋白制备及其用途 | |
KR102162934B1 (ko) | Lrg1 당단백질을 포함하는 융합 단백질을 함유하는 발기부전, 허혈성 질환 또는 말초 신경질환의 예방 또는 치료용 조성물 | |
RU2797520C2 (ru) | СЛИТЫЙ ПОЛИПЕПТИД, ВКЛЮЧАЮЩИЙ Fc ОБЛАСТЬ ИММУНОГЛОБУЛИНА И GDF15 | |
KR20180136418A (ko) | hGH 융합단백질을 포함하는 성장호르몬 결핍을 치료하기 위한 약학 조성물 | |
KR101792205B1 (ko) | 혈중 지속성 연장을 위한 항체 Fc 변이체들 | |
JP2023503472A (ja) | 長時間作用型gdf15融合タンパク質およびそれを含む医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211021 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221017 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230320 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230620 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230807 |